Climb Bio Inc (CLYM) — Cash Flow-to-Debt Ratio
Climb Bio Inc (CLYM) has a Cash Flow-to-Debt Ratio of -3.35x as of March 2026, meaning its operating cash flow of $-14.38 Million could theoretically repay -3% of its total liabilities ($4.29 Million) in one year. See CLYM free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Climb Bio Inc Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Climb Bio Inc across 7 annual periods. Also explore CLYM net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Climb Bio Inc (2019–2025)
Year-by-year debt coverage analysis for Climb Bio Inc. For market capitalisation and broader financial context, see CLYM market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -7.48x | $-54.36 Million | $7.27 Million | ▼ -155.0% |
| 2024 | -2.93x | $-15.56 Million | $5.31 Million | ▲ +59.1% |
| 2023 | -7.18x | $-20.60 Million | $2.87 Million | ▼ -20.6% |
| 2022 | -5.95x | $-37.37 Million | $6.28 Million | ▲ +0.3% |
| 2021 | -5.97x | $-36.07 Million | $6.04 Million | ▼ -29.8% |
| 2020 | -4.60x | $-14.10 Million | $3.06 Million | ▲ +28.0% |
| 2019 | -6.40x | $-5.01 Million | $783.00K | — |